RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

Sponsor
AstraZeneca
Study ID
NCT05933044
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Chemoradiotherapy plus durvalumab

Study Details

In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres. Subsequent analyses will examine treatment patterns and clinical outcomes, including overall survival, for these patients, stratified by durvalumab regimen or non-durvalumab regimen during the time of the PACIFIC Patient Support Program.

Key Dates

Start date
Nov 19, 2021
Status verified
Aug 2023
Primary completion
Aug 31, 2022
Completion
Aug 31, 2022

Study Design

Enrollment
662 participants (actual)

Arms

  • Arm: Durvalumab cohort
    All stage III non-small cell lung cancer (NSCLC) patients who received durvalumab
  • Arm: Non-durvalumab cohort
    All stage III non-small cell lung cancer (NSCLC) patients who did not receive durvalumab

Primary Outcome Measure

Overall survival [ Time Frame: November 1, 2017 to August 31, 2022 ]

Related Studies